Clinical Features of Venous Thromboembolism in Patients With Coronavirus Disease 2019 (COVID-19) in Japan　― A Case Series Study ―

Background: Amitraz is a pharmaceutical, veterinary, and agricultural product which is used worldwide to control ectoparasites in animals. Its widespread use has led to increased cases of poisoning in rural parts of India. Aim: To study the clinical features, complications, laboratory abnormalities and outcome of the patients with acute amitraz intoxication. Methodology: The study is a retrospective case series study conducted in HSK hospital between the period of Feb 2019 and May 2020. Results: A total of 11 patients were analysed and results revealed CNS depression and vomiting in 8 of those patients with 1 patient with respiratory failure requiring mechanical ventilation. Conclusion: Amitraz poisoning appears to be severe with CNS depression being the most common symptom. But most patients stabilise and recover quickly. Patients should be monitored for respiratory failure as it is a dreadful complication. Treatment is symptomatic as no antidote is available.

Download Full-text

Clinical features and neuroimaging (CT and MRI) findings in presumed Zika virus related congenital infection and microcephaly: retrospective case series study

BMJ ◽

10.1136/bmj.i3182 ◽

2016 ◽

pp. i3182 ◽

Cited By ~ 4

Keyword(s):

Clinical Features ◽

Zika Virus ◽

Case Series ◽

Congenital Infection ◽

Mri Findings ◽

Retrospective Case ◽

Retrospective Case Series ◽

Case Series Study ◽

Series Study ◽

Ct And Mri

Download Full-text

Clinical Features of Skin Infection After Rhinoplasty with Only Absorbable Thread (Polydioxanone) in Oriental Traditional Medicine: A Case Series Study

Aesthetic Plastic Surgery ◽

10.1007/s00266-019-01550-y ◽

2019 ◽

Vol 44 (1) ◽

pp. 139-147

Author(s):

Hyeon Jo Kim ◽

Seong Joo Lee ◽

Ju Ho Lee ◽

Seong Hwan Kim ◽

In Suck Suh ◽

...

Keyword(s):

Traditional Medicine ◽

Clinical Features ◽

Skin Infection ◽

Case Series ◽

Case Series Study ◽

Series Study

Download Full-text

Clinical Profile and CT-Chest Patterns of 56 Patients with Covid-19 Pneumonia

AL-MUKHTAR JOURNAL OF SCIENCES ◽

10.54172/mjsc.v35i4.334 ◽

2020 ◽

Vol 35 (4) ◽

pp. 304-312

Author(s):

Olla A M Ibrahim ◽

Enas M Alhaen ◽

Walid A S Mohmmed ◽

Wadyan M A Salh

Keyword(s):

Clinical Features ◽

False Negative ◽

Case Series ◽

Patients Âgés ◽

Halo Sign ◽

Local Case ◽

Case Series Study ◽

Primary Reference ◽

Contrast Ct ◽

Series Study

Since the COVID-19 pandemic was announced, the concern of radiologists and physicians regarding its diagnosis has been profoundly raised. The primary reference for confirming COVID-19 pneumonia relies on reverse transcriptase-polymerase chain reaction (RT-PCR) testing, where the subject of availability, false negative-rates, practice dependency, and time-consumption, made computed tomography (CT) more superior in Covid-19 pneumonia diagnosis, which was the situation in Al-Baida-city\Libya. The first local case in Al-Baida-city was reported on 30 July 2020, followed by a dramatic surge in the number of cases, which necessitated the recognition of main clinical features and CT-patterns of COVID-19 to facilitate rapid diagnosis. The aim of study: Describe the clinical features and the CT-chest patterns of COVID-19 pneumonia among the studied population. A descriptive case series study was conducted in the central hospital of Al-Baida city /Libya from 11 August to 21 September 2020, which involved 56 patients (31 females and 25 males). Patients’ ages ranged from 28-88 years (62.79± 11.3). Non-contrast CT-chest was performed on all patients. The main patients’ complaints were fever 94.6%, dyspnea 89.3%, and cough 85.7%. The most common CT pattern among the studied cases was ground-glass opacities found in 100% of patients, followed by vascular thickening 88%, consolidative lesion 71.4%, crazy-paving pattern 57%, vacuolar sign 57.1%, architecture distortion 40%, halo sign 34%, reverse halo sign 34.5%, and traction-bronchiectasis 16% of the studied cases. Finally, recognition of CT-chest patterns of Covid-19 pneumonia plays a significant role in early detection, and therefore isolation and management of the disease. The findings of this study can be used as a baseline for further research in the future.

Download Full-text

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study

BMJ ◽

10.1136/bmj.n1931 ◽

2021 ◽

pp. n1931 ◽

Cited By ~ 6

Author(s):

Julia Hippisley-Cox ◽

Martina Patone ◽

Xue W Mei ◽

Defne Saatci ◽

Sharon Dixon ◽

...

Keyword(s):

Venous Thromboembolism ◽

Hospital Admission ◽

Ischaemic Stroke ◽

Case Series ◽

Positive Test ◽

Vascular Events ◽

Arterial Thromboembolism ◽

Case Series Study ◽

Increased Risk ◽

Series Study

Abstract Objective To assess the association between covid-19 vaccines and risk of thrombocytopenia and thromboembolic events in England among adults. Design Self-controlled case series study using national data on covid-19 vaccination and hospital admissions. Setting Patient level data were obtained for approximately 30 million people vaccinated in England between 1 December 2020 and 24 April 2021. Electronic health records were linked with death data from the Office for National Statistics, SARS-CoV-2 positive test data, and hospital admission data from the United Kingdom’s health service (NHS). Participants 29 121 633 people were vaccinated with first doses (19 608 008 with Oxford-AstraZeneca (ChAdOx1 nCoV-19) and 9 513 625 with Pfizer-BioNTech (BNT162b2 mRNA)) and 1 758 095 people had a positive SARS-CoV-2 test. People aged ≥16 years who had first doses of the ChAdOx1 nCoV-19 or BNT162b2 mRNA vaccines and any outcome of interest were included in the study. Main outcome measures The primary outcomes were hospital admission or death associated with thrombocytopenia, venous thromboembolism, and arterial thromboembolism within 28 days of three exposures: first dose of the ChAdOx1 nCoV-19 vaccine; first dose of the BNT162b2 mRNA vaccine; and a SARS-CoV-2 positive test. Secondary outcomes were subsets of the primary outcomes: cerebral venous sinus thrombosis (CVST), ischaemic stroke, myocardial infarction, and other rare arterial thrombotic events. Results The study found increased risk of thrombocytopenia after ChAdOx1 nCoV-19 vaccination (incidence rate ratio 1.33, 95% confidence interval 1.19 to 1.47 at 8-14 days) and after a positive SARS-CoV-2 test (5.27, 4.34 to 6.40 at 8-14 days); increased risk of venous thromboembolism after ChAdOx1 nCoV-19 vaccination (1.10, 1.02 to 1.18 at 8-14 days) and after SARS-CoV-2 infection (13.86, 12.76 to 15.05 at 8-14 days); and increased risk of arterial thromboembolism after BNT162b2 mRNA vaccination (1.06, 1.01 to 1.10 at 15-21 days) and after SARS-CoV-2 infection (2.02, 1.82 to 2.24 at 15-21 days). Secondary analyses found increased risk of CVST after ChAdOx1 nCoV-19 vaccination (4.01, 2.08 to 7.71 at 8-14 days), after BNT162b2 mRNA vaccination (3.58, 1.39 to 9.27 at 15-21 days), and after a positive SARS-CoV-2 test; increased risk of ischaemic stroke after BNT162b2 mRNA vaccination (1.12, 1.04 to 1.20 at 15-21 days) and after a positive SARS-CoV-2 test; and increased risk of other rare arterial thrombotic events after ChAdOx1 nCoV-19 vaccination (1.21, 1.02 to 1.43 at 8-14 days) and after a positive SARS-CoV-2 test. Conclusion Increased risks of haematological and vascular events that led to hospital admission or death were observed for short time intervals after first doses of the ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines. The risks of most of these events were substantially higher and more prolonged after SARS-CoV-2 infection than after vaccination in the same population.

Download Full-text